List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3072294/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Derivatization procedures for gas chromatographic–mass spectrometric determination of xenobiotics in biological samples, with special attention to drugs of abuse and doping agents. Biomedical Applications, 1998, 713, 61-90.	1.7	223
2	Prenatal exposure to bisphenol AÂand phthalates and childhood respiratory tract infections and allergy. Journal of Allergy and Clinical Immunology, 2015, 135, 370-378.e7.	2.9	203
3	Prenatal Phthalate Exposure and Childhood Growth and Blood Pressure: Evidence from the Spanish INMA-Sabadell Birth Cohort Study. Environmental Health Perspectives, 2015, 123, 1022-1029.	6.0	147
4	Exposure to Bisphenol A and Phthalates during Pregnancy and Ultrasound Measures of Fetal Growth in the INMA-Sabadell Cohort. Environmental Health Perspectives, 2016, 124, 521-528.	6.0	119
5	Variability and predictors of urinary phthalate metabolites in Spanish pregnant women. International Journal of Hygiene and Environmental Health, 2015, 218, 220-231.	4.3	108
6	Use of LC-MS/MS for the Open Detection of Steroid Metabolites Conjugated with Glucuronic Acid. Analytical Chemistry, 2013, 85, 5005-5014.	6.5	93
7	Prenatal exposure to phthalates and neuropsychological development during childhood. International Journal of Hygiene and Environmental Health, 2015, 218, 550-558.	4.3	87
8	Detection of diuretic agents in doping control. Biomedical Applications, 1996, 687, 127-144.	1.7	82
9	Progress in the Removal of Di-[2-Ethylhexyl]-Phthalate as Plasticizer in Blood Bags. Transfusion Medicine Reviews, 2012, 26, 27-37.	2.0	78
10	Analytical strategies based on mass spectrometric techniques for the study of steroid metabolism. TrAC - Trends in Analytical Chemistry, 2014, 53, 106-116.	11.4	74
11	Targeting tryptophan and tyrosine metabolism by liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2016, 1434, 91-101.	3.7	72
12	Alternative long-term markers for the detection of methyltestosterone misuse. Steroids, 2013, 78, 44-52.	1.8	67
13	Discrimination of Prohibited Oral Use of Salbutamol from Authorized Inhaled Asthma Treatment. Clinical Chemistry, 2000, 46, 1365-1375.	3.2	65
14	Derivatization procedures for the detection of ?2-agonists by gas chromatographic/mass spectrometric analysis. Journal of Mass Spectrometry, 2000, 35, 1285-1294.	1.6	64
15	High-Throughput and Sensitive Screening by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry of Diuretics and other Doping Agents. European Journal of Mass Spectrometry, 2008, 14, 191-200.	1.0	63
16	Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. Analytica Chimica Acta, 2014, 812, 92-104.	5.4	60
17	New potential markers for the detection of boldenone misuse. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 239-246.	2.5	59
18	A new sulphate metabolite as a long-term marker of metandienone misuse. Steroids, 2013, 78, 1245-1253.	1.8	57

#	Article	IF	CITATIONS
19	Detection of non-steroidal anti-inflammatory drugs in equine plasma and urine by gas chromatography-mass spectrometry. Journal of Chromatography A, 1996, 719, 251-264.	3.7	56
20	Analytical methodology for the detection of β2-agonists in urine by gas chromatography–mass spectrometry for application in doping control. Analytica Chimica Acta, 2000, 418, 79-92.	5.4	55
21	Analytical methodology for enantiomers of salbutamol in human urine for application in doping control. Biomedical Applications, 1999, 723, 173-184.	1.7	53
22	Fast screening method for diuretics, probenecid and other compounds of doping interest. Journal of Chromatography A, 1993, 655, 233-242.	3.7	50
23	Validation of qualitative chromatographic methods: strategy in antidoping control laboratories. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 767, 341-351.	2.3	49
24	Stability studies of amphetamine and ephedrine derivatives in urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 84-93.	2.3	46
25	Evaluation of different scan methods for the urinary detection of corticosteroid metabolites by liquid chromatography tandem mass spectrometry. Journal of Mass Spectrometry, 2009, 44, 929-944.	1.6	46
26	Comparison between triple quadrupole, time of flight and hybrid quadrupole time of flight analysers coupled to liquid chromatography for the detection of anabolic steroids in doping control analysis. Analytica Chimica Acta, 2011, 684, 107-120.	5.4	46
27	Testosterone metabolism revisited: discovery of new metabolites. Analytical and Bioanalytical Chemistry, 2010, 398, 1759-1770.	3.7	43
28	Distinction of Inhaled and Oral Salbutamol by Urine Analysis Using Conventional Screening Procedures for Doping Control. Therapeutic Drug Monitoring, 2000, 22, 277-282.	2.0	43
29	Diagnostic evidence for the presence of β-agonists using two consecutive derivatization procedures and gas chromatography–mass spectrometric analysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 61-71.	2.3	42
30	Quantifying endogenous androgens, estrogens, pregnenolone and progesterone metabolites in human urine by gas chromatography tandem mass spectrometry. Talanta, 2017, 169, 20-29.	5.5	40
31	Urinary diâ€{2â€ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison study with patients receiving blood transfusion. Transfusion, 2010, 50, 145-149.	1.6	39
32	Untargeted Metabolomics in Doping Control: Detection of New Markers of Testosterone Misuse by Ultrahigh Performance Liquid Chromatography Coupled to High-Resolution Mass Spectrometry. Analytical Chemistry, 2015, 87, 8373-8380.	6.5	39
33	Identification of budesonide metabolites in human urine after oral administration. Analytical and Bioanalytical Chemistry, 2012, 404, 325-340.	3.7	37
34	Detection, synthesis and characterization of metabolites of steroid hormones conjugated with cysteine. Steroids, 2013, 78, 327-336.	1.8	37
35	Screening for anabolic steroids in sports: Analytical strategy based on the detection of phase I and phase II intact urinary metabolites by liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2015, 1389, 65-75.	3.7	37
36	Pseudoephedrine and circadian rhythm interaction on neuromuscular performance. Scandinavian Journal of Medicine and Science in Sports, 2015, 25, e603-12.	2.9	37

#	Article	IF	CITATIONS
37	Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Analytical and Bioanalytical Chemistry, 2011, 401, 517-528.	3.7	36
38	Determination of five di-(2-ethylhexyl)phthalate metabolites in urine by UPLC–MS/MS, markers of blood transfusion misuse in sports. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 908, 113-121.	2.3	36
39	Stability studies of selected doping agents in urine: caffeine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 795, 167-177.	2.3	35
40	Plasticizers excreted in urine: indication of autologous blood transfusion in sports. Transfusion, 2012, 52, 647-657.	1.6	35
41	Approach to the analysis of diuretics and masking agents by high-performance liquid chromatography—mass spectrometry in doping control. Biomedical Applications, 1991, 562, 723-736.	1.7	33
42	Mass spectrometric behavior of anabolic androgenic steroids using gas chromatography coupled to atmospheric pressure chemical ionization source. Part I: Ionization. Journal of Mass Spectrometry, 2014, 49, 509-521.	1.6	33
43	International cooperation in analytical chemistry: experience of antidoping control at the XI Pan American Games. Clinical Chemistry, 1993, 39, 836-845.	3.2	32
44	Quantitation of 17β-nandrolone metabolites in boar and horse urine by gas chromatography–mass spectrometry. Analytica Chimica Acta, 2007, 586, 184-195.	5.4	32
45	Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry. Journal of Mass Spectrometry, 2001, 36, 652-657.	1.6	31
46	Stability of Drugs of Abuse in Oral Fluid Collection Devices With Purpose of External Quality Assessment Schemes. Therapeutic Drug Monitoring, 2009, 31, 277-280.	2.0	31
47	Detection of dihydrotestosterone gel, oral dehydroepiandrosterone, and testosterone gel misuse through the quantification of testosterone metabolites released after alkaline treatment. Drug Testing and Analysis, 2011, 3, 828-835.	2.6	31
48	Urinary profile of methylprednisolone and its metabolites after oral and topical administrations. Journal of Steroid Biochemistry and Molecular Biology, 2013, 138, 214-221.	2.5	31
49	Constant Ion Loss Method for the Untargeted Detection of Bis-sulfate Metabolites. Analytical Chemistry, 2017, 89, 1602-1609.	6.5	31
50	Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport. Clinical Chemistry and Laboratory Medicine, 2005, 43, 75-85.	2.3	30
51	Urinary metabolic profile of 19â€norsteroids in humans: glucuronide and sulphate conjugates after oral administration of 19â€norâ€4â€androstenediol. Rapid Communications in Mass Spectrometry, 2008, 22, 3035-3042.	1.5	29
52	Pharmacokinetics of buprenorphine after intravenous administration of clinical doses to dogs. Veterinary Journal, 2009, 181, 299-304.	1.7	29
53	Alternative markers for the long-term detection of oral testosterone misuse. Steroids, 2011, 76, 1367-1376.	1.8	29
54	Using complementary mass spectrometric approaches for the determination of methylprednisolone metabolites in human urine. Rapid Communications in Mass Spectrometry, 2012, 26, 541-553	1.5	29

#	Article	IF	CITATIONS
55	Potential of atmospheric pressure chemical ionization source in gas chromatography tandem mass spectrometry for the screening of urinary exogenous androgenic anabolic steroids. Analytica Chimica Acta, 2016, 906, 128-138.	5.4	29
56	Stability studies of testosterone and epitestosterone glucuronides in urine. Rapid Communications in Mass Spectrometry, 2006, 20, 858-864.	1.5	28
57	Discrimination of Prohibited Oral Use From Authorized Inhaled Treatment of Budesonide in Sports. Therapeutic Drug Monitoring, 2013, 35, 118-128.	2.0	27
58	Detection and characterization of clostebol sulfate metabolites in Caucasian population. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 54-63.	2.3	27
59	Direct quantitation of endogenous steroid sulfates in human urine by liquid chromatographyâ€electrospray tandem mass spectrometry. Drug Testing and Analysis, 2018, 10, 1734-1743.	2.6	27
60	Screening Procedure for β-Adrenergic Drugs in Sports Drug Testing by Immunological Methods. Journal of Analytical Toxicology, 1998, 22, 127-134.	2.8	26
61	HAIRVEQ: an external quality control scheme for drugs of abuse analysis in hair. Forensic Science International, 2004, 145, 109-115.	2.2	26
62	Evaluation of immunoassays for the measurement of erythropoietin (EPO) as an indirect biomarker of recombinant human EPO misuse in sport. Journal of Pharmaceutical and Biomedical Analysis, 2004, 35, 1169-1177.	2.8	26
63	Detection and characterization of urinary metabolites of boldione by LCâ€MS/MS. Part I: Phase I metabolites excreted free, as glucuronide and sulfate conjugates, and released after alkaline treatment of the urine. Drug Testing and Analysis, 2012, 4, 775-785.	2.6	26
64	Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS. Journal of Mass Spectrometry, 2015, 50, 633-642.	1.6	26
65	Ultraperformance liquid chromatography tandem mass spectrometric method for direct quantification of salbutamol in urine samples in doping control. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 886-890.	2.8	25
66	Evaluation of two glucuronides resistant to enzymatic hydrolysis as markers of testosterone oral administration. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 212-218.	2.5	25
67	Detection of erythropoiesisâ€stimulating agents in a single dried blood spot. Drug Testing and Analysis, 2018, 10, 1496-1507.	2.6	25
68	Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 768, 315-324.	2.3	24
69	Sensitive and robust method for anabolic agents in human urine by gas chromatography–triple quadrupole mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 897, 85-89.	2.3	24
70	Determination of mesocarb metabolites by high-performance liquid chromatography with UV detection and with mass spectrometry using a particle-beam interface. Journal of Chromatography A, 1993, 647, 203-210.	3.7	23
71	Application of pericardial fluid to the analysis of morphine (heroin) and cocaine in forensic toxicology. Forensic Science International, 2006, 164, 168-171.	2.2	23
72	Growth Hormone in Sport: Beyond Beijing 2008. Therapeutic Drug Monitoring, 2009, 31, 3-13.	2.0	23

#	Article	IF	CITATIONS
73	Mass spectrometric characterization of urinary toremifene metabolites for doping control analyses. Journal of Chromatography A, 2011, 1218, 4727-4737.	3.7	23
74	Quantification of perphenazine in Eurasian otter (Lutra lutra lutra) urine samples by gas chromatography–mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 769, 79-87.	2.3	22
75	Plasma buprenorphine concentrations after the application of a 70â€∫î¼g/h transdermal patch in dogs. Preliminary report. Journal of Veterinary Pharmacology and Therapeutics, 2009, 32, 503-505.	1.3	22
76	A Partially Automated Pretreatment Module for Routine Analyses for Seventeen Non-Steroid Antiinflammatory Drugs in Race Horses Using Gas Chromatography/Mass Spectrometry. Analytical Chemistry, 1996, 68, 118-123.	6.5	21
77	Quantification of testosterone and metabolites released after alkaline treatment in human urine. Drug Testing and Analysis, 2010, 2, 630-636.	2.6	21
78	Detection and characterization of triamcinolone acetonide metabolites in human urine by liquid chromatography/tandem mass spectrometry after intramuscular administration. Rapid Communications in Mass Spectrometry, 2014, 28, 1829-1839.	1.5	21
79	Stability Studies of Principal Illicit Drugs in Oral Fluid: Preparation of Reference Materials for External Quality Assessment Schemes. Therapeutic Drug Monitoring, 2007, 29, 662-665.	2.0	20
80	Sulfate metabolites improve retrospectivity after oral testosterone administration. Drug Testing and Analysis, 2019, 11, 392-402.	2.6	20
81	Validation of a Procedure for the Gas Chromatography-Mass Spectrometry Analysis of Cocaine and Metabolites in Pericardial Fluid. Journal of Analytical Toxicology, 2007, 31, 75-80.	2.8	19
82	Detection and characterization of betamethasone metabolites in human urine by LCâ€MS/MS. Drug Testing and Analysis, 2015, 7, 663-672.	2.6	19
83	Evaluation of sulfate metabolites as markers of intramuscular testosterone administration in Caucasian and Asian populations. Drug Testing and Analysis, 2019, 11, 1218-1230.	2.6	19
84	Strategies for internal quality control in antidoping analyses. Analytica Chimica Acta, 2002, 460, 289-307.	5.4	18
85	Effect of Physical Fitness and Endurance Exercise on Indirect Biomarkers of Recombinant Erythropoietin Misuse. International Journal of Sports Medicine, 2007, 28, 9-15.	1.7	18
86	Recent developments in MS for small molecules: application to human doping control analysis. Bioanalysis, 2012, 4, 197-212.	1.5	18
87	Evaluation of urinary excretion of androgens conjugated to cysteine in human pregnancy by mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2014, 139, 192-200.	2.5	18
88	Evaluation of the reporting level to detect triamcinolone acetonide misuse in sports. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 94-102.	2.5	18
89	Protocols for stability and homogeneity studies of drugs for its application to doping control. Analytica Chimica Acta, 2004, 515, 323-331.	5.4	17
90	Alterations of the erythrocyte membrane proteome and cytoskeleton network during storage – a possible tool to identify autologous blood transfusion. Drug Testing and Analysis, 2012, 4, 882-890.	2.6	17

#	Article	IF	CITATIONS
91	Detection methods for autologous blood doping. Drug Testing and Analysis, 2012, 4, 876-881.	2.6	17
92	Ultra high performance liquid chromatography tandem mass spectrometric detection of glucuronides resistant to enzymatic hydrolysis: Implications to doping control analysis. Analytica Chimica Acta, 2015, 895, 35-44.	5.4	17
93	Detection of stanozolol <i>Oâ€</i> and <i>Nâ€</i> sulfate metabolites and their evaluation as additional markers in doping control. Drug Testing and Analysis, 2017, 9, 1001-1010.	2.6	17
94	Evaluation of immunoassays for the measurement of soluble transferrin receptor as an indirect biomarker of recombinant human erythropoietin misuse in sport. Journal of Immunological Methods, 2004, 295, 89-99.	1.4	16
95	Reference materials for analytical toxicology including doping control: freeze-dried urine samples. Analyst, The, 2004, 129, 449-455.	3.5	16
96	Effect of Physical Fitness and Endurance Exercise on Indirect Biomarkers of Recombinant Growth Hormone Misuse: Insulin-Like Growth Factor I and Procollagen Type III Peptide. International Journal of Sports Medicine, 2006, 27, 976-983.	1.7	16
97	Detection of the administration of 17 <i>β</i> â€nortestosterone in boars by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 1863-1870.	1.5	16
98	Current status and bioanalytical challenges in the detection of unknown anabolic androgenic steroids in doping control analysis. Bioanalysis, 2013, 5, 2661-2677.	1.5	16
99	Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part I: Transdermal administration. Drug Testing and Analysis, 2018, 10, 821-831.	2.6	16
100	Additional studies on triamcinolone acetonide use and misuse in sports: Elimination profile after intranasal and high-dose intramuscular administrations. Steroids, 2019, 151, 108464.	1.8	16
101	Immunoassays for the measurement of IGF-II, IGFBP-2 and -3, and ICTP as indirect biomarkers of recombinant human growth hormone misuse in sport. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 844-852.	2.8	15
102	Detection and characterization of urinary metabolites of boldione by LCâ€MS/MS. Part II: Conjugates with cysteine and <i>N</i> â€acetylcysteine. Drug Testing and Analysis, 2012, 4, 786-797.	2.6	15
103	Evaluation of fibronectin 1 in one dried blood spot and in urine after rhGH treatment. Drug Testing and Analysis, 2017, 9, 1011-1016.	2.6	15
104	Evaluation of immunoassays for the measurement of insulin and C-peptide as indirect biomarkers of insulin misuse in sport: Values in selected population of athletes. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 793-799.	2.8	14
105	Screening method for stimulants in urine by UHPLCâ€MS/MS: identification of isomeric compounds. Drug Testing and Analysis, 2015, 7, 819-830.	2.6	14
106	Genetic and protein biomarkers in blood for the improved detection of GH abuse. Journal of Pharmaceutical and Biomedical Analysis, 2016, 128, 111-118.	2.8	14
107	A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. British Journal of Sports Medicine, 2021, 55, 631-642.	6.7	14
108	Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clinical Chemistry, 2000, 46, 1365-75.	3.2	14

#	Article	IF	CITATIONS
109	Can glycans unveil the origin of glycoprotein hormones?—human chorionic gonadotrophin as an example—. Journal of Mass Spectrometry, 2008, 43, 936-948.	1.6	13
110	Identification of free and conjugated metabolites of mesocarb in human urine by LC-MS/MS. Analytical and Bioanalytical Chemistry, 2010, 397, 2903-2916.	3.7	12
111	Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 1003-1010.	2.8	12
112	Sulfate metabolites as alternative markers for the detection of 4 hlorometandienone misuse in doping control. Drug Testing and Analysis, 2017, 9, 983-993.	2.6	12
113	Evaluation of markers out of the steroid profile for the screening of testosterone misuse. Part II: Intramuscular administration. Drug Testing and Analysis, 2018, 10, 849-859.	2.6	12
114	Intermittent hypoxia exposure in a hypobaric chamber and erythropoietin abuse interpretation. Journal of Sports Sciences, 2007, 25, 1241-1250.	2.0	11
115	Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study. Orphanet Journal of Rare Diseases, 2014, 9, 54.	2.7	11
116	Bioanalytical techniques in discrimination between therapeutic and abusive use of drugs in sport. Bioanalysis, 2016, 8, 965-980.	1.5	11
117	Effect of glucocorticoid administration on the steroid profile. Drug Testing and Analysis, 2018, 10, 947-955.	2.6	11
118	Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intraâ€articular administration. Drug Testing and Analysis, 2019, 11, 1589-1600.	2.6	11
119	Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, highâ€dose inhaled and oral administrations. Drug Testing and Analysis, 2020, 12, 629-636.	2.6	11
120	Gas chromatography–mass spectrometry method for the analysis of 19-nor-4-androstenediol and metabolites in human plasma: Application to pharmacokinetic studies after oral administration of a prohormone supplement. Steroids, 2008, 73, 751-759.	1.8	10
121	Urinary cysteinyl progestogens: Occurrence and origin. Journal of Steroid Biochemistry and Molecular Biology, 2015, 152, 53-61.	2.5	10
122	Synthesis and characterization of 6βâ€hydroxyandrosterone and 6βâ€hydroxyetiocholanolone conjugated with glucuronic acid. Drug Testing and Analysis, 2015, 7, 247-252.	2.6	10
123	Evaluation of uncertainty sources in the determination of testosterone in urine by calibration-based and isotope dilution quantification using ultra high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2017, 1508, 73-80.	3.7	10
124	Elimination profiles of prednisone and prednisolone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. Drug Testing and Analysis, 2021, 13, 571-582.	2.6	10
125	Detection in urine of efaproxiral (RSR13), a potential doping agent, by a routine screening procedure based on methylation followed by gas chromatography/mass spectrometry. Analytica Chimica Acta, 2004, 505, 227-229.	5.4	9
126	ORALVEQ: External quality assessment scheme of drugs of abuse in oral fluid. Forensic Science International, 2008, 182, 35-40.	2.2	9

#	Article	lF	CITATIONS
127	Enzyme-linked immunosorbent assays for doping control of 5α-reductase inhibitors finasteride and dutasteride. Analytica Chimica Acta, 2010, 671, 70-79.	5.4	9
128	Enzyme-linked immunosorbent assays for the synthetic steroid gestrinone. Talanta, 2010, 82, 1581-1587.	5.5	9
129	Current strategic approaches for the detection of blood doping practices. Forensic Science International, 2011, 213, 42-48.	2.2	9
130	Masking and Manipulation. Handbook of Experimental Pharmacology, 2009, , 327-354.	1.8	9
131	International cooperation in analytical chemistry: experience of antidoping control at the XI Pan American Games. Clinical Chemistry, 1993, 39, 836-45.	3.2	9
132	Four Years' Experience in External Proficiency Testing Programs for Hair Testing of Drugs of Abuse in Italy (HAIRVEQ) and Comparison With the Society of Hair Testing Program in 2005. Therapeutic Drug Monitoring, 2007, 29, 11-19.	2.0	8
133	Clarification on the detection of epoetin delta and epoetin omega using isoelectric focusing. American Journal of Hematology, 2008, 83, 754-754.	4.1	8
134	HAIRVEQ 2006: Evolution of laboratories' performance after different educational actions. Forensic Science International, 2008, 176, 2-8.	2.2	8
135	Evaluation of the urinary threshold concentration of formoterol in sports drug testing. Drug Testing and Analysis, 2013, 5, 266-269.	2.6	8
136	LCâ€MS/MS detection of unaltered glucuronoconjugated metabolites of metandienone. Drug Testing and Analysis, 2017, 9, 534-544.	2.6	8
137	Formation of Δ1 and Δ6 testosterone metabolites by human hepatocytes. Steroids, 2015, 95, 66-72.	1.8	7
138	Factors affecting urinary excretion of testosterone metabolites conjugated with cysteine. Drug Testing and Analysis, 2016, 8, 110-119.	2.6	7
139	Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry. Journal of Chromatography A, 2020, 1631, 461548.	3.7	7
140	Elimination profiles of betamethasone after different administration routes: Evaluation of the reporting level and washout periods to ensure safe therapeutic administrations. Drug Testing and Analysis, 2021, 13, 348-359.	2.6	7
141	Analysis of naltrexone urinary metabolites. Journal of Pharmaceutical and Biomedical Analysis, 1988, 6, 887-893.	2.8	5
142	Chapter 15 Doping substances in human and animal sport. Handbook of Analytical Separations, 2000, 2, 531-566.	0.8	5
143	Ionization and collision induced dissociation of steroid bisglucuronides. Journal of Mass Spectrometry, 2017, 52, 759-769.	1.6	5
144	The effect of tea consumption on the steroid profile. Drug Testing and Analysis, 2018, 10, 1438-1447.	2.6	5

#	Article	IF	CITATIONS
145	Chapter 21 Doping substances in human and animal sport. Handbook of Analytical Separations, 2008, , 699-744.	0.8	4
146	Analysis of hydroxylated phenylalkylamine stimulants in urine by GC-APPI-HRMS. Analytical and Bioanalytical Chemistry, 2020, 412, 7837-7850.	3.7	4
147	Multiple headspace solid-phase microextraction (MHS-SPME) methodology applied to the determination of volatile metabolites of plasticizers in human urine. Microchemical Journal, 2022, 180, 107567.	4.5	4
148	High-Resolution Mass Spectrometry in Doping Control. Comprehensive Analytical Chemistry, 2016, , 91-117.	1.3	3
149	New approach based on immunochemical techniques for monitoring of selective estrogen receptor modulators (SERMs) in human urine. Journal of Pharmaceutical and Biomedical Analysis, 2018, 156, 147-152.	2.8	3
150	If you play with fire, you may get burned. Drug Testing and Analysis, 2020, 12, 582-587.	2.6	3
151	Qualitative evaluation of chromatographic data from quality control schemes using a support vector machine. Analyst, The, 2008, 133, 105-111.	3.5	2
152	Response to Letter to the Editor regarding "Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing― Analytical and Bioanalytical Chemistry, 2011, 401, 579-580.	3.7	2
153	Mass spectrometric characterisation of a condensation product between porphobilinogen and indolylâ€3â€acryloylglycine in urine of patients with acute intermittent porphyria. Journal of Mass Spectrometry, 2015, 50, 929-937.	1.6	1
154	Protocols for stability and homogeneity studies of drugs for its application to doping control. Analytica Chimica Acta, 2004, 515, 323-323.	5.4	0
155	Research Spotlight: Bioanalysis and Analytical Services Research Group at The Municipal Institute for Medical Research IMIM-Hospital del Mar, Spain. Bioanalysis, 2009, 1, 1403-1409.	1.5	0
156	Corrigendum to "Genetic and protein biomarkers in blood for the improved detection of GH abuse―[J. Pharm. Biomed. Anal. 128 (2016) 111–118, doi: 10.1016/j.jpba.2016.05.022.]. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 385.	2.8	0